Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) Net Margin (2018 - 2025)

Historic Net Margin for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to 503.66%.

  • Bicycle Therapeutics' Net Margin rose 13947700.0% to 503.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 4369.94%, marking a year-over-year increase of 70993600.0%. This contributed to the annual value of 14085.92% for FY2024, which is 106771600.0% down from last year.
  • Latest data reveals that Bicycle Therapeutics reported Net Margin of 503.66% as of Q3 2025, which was up 13947700.0% from 2703.84% recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' Net Margin ranged from a high of 300.39% in Q4 2023 and a low of 2703.84% during Q2 2025
  • Its 5-year average for Net Margin is 781.25%, with a median of 608.94% in 2025.
  • Its Net Margin has fluctuated over the past 5 years, first skyrocketed by 18977400bps in 2022, then plummeted by -22785400bps in 2025.
  • Over the past 5 years, Bicycle Therapeutics' Net Margin (Quarter) stood at 2254.62% in 2021, then skyrocketed by 84bps to 356.88% in 2022, then surged by 184bps to 300.39% in 2023, then plummeted by -43bps to 170.76% in 2024, then crashed by -395bps to 503.66% in 2025.
  • Its Net Margin stands at 503.66% for Q3 2025, versus 2703.84% for Q2 2025 and 608.94% for Q1 2025.